<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005859</url>
  </required_header>
  <id_info>
    <org_study_id>01-18-16</org_study_id>
    <nct_id>NCT04005859</nct_id>
  </id_info>
  <brief_title>Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane</brief_title>
  <acronym>Exparel</acronym>
  <official_title>Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the analgesic impact of intravenous perioperative lidocaine infusion with&#xD;
      preoperative liposomal bupivacaine TAP block in colorectal surgery. This is to be integrated&#xD;
      into the standard ERAS protocol currently utilized at Carolinas Medical Center. Primary&#xD;
      endpoints will be postoperative pain as measured by verbal rate scale (VRS), postoperative&#xD;
      morphine equivalents utilized per day, and over 30 days. Secondary endpoints will include&#xD;
      date of ambulation, return of bowel function (first flatus), tolerance of goal diet,&#xD;
      incidence of post-operative nausea and vomiting during hospital stay, length of stay&#xD;
      (hospital and PACU), post-operative morbidity (Clavien-Dindo, related to both anesthesia and&#xD;
      surgery), cost of hospitalization (operative, PACU, postoperative stay, and total) and&#xD;
      quality of life on follow up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2018</start_date>
  <completion_date type="Actual">July 20, 2021</completion_date>
  <primary_completion_date type="Actual">May 9, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Verbal Pain Scale (VRS) - 4 Week Post-op</measure>
    <time_frame>Single VRS assessed at 4-week post-op visit (or phone call)</time_frame>
    <description>Postoperative pain was measured by verbal rate scale (VRS) Scale of 0-10 at instance of 4-week post-op visit (or phone call). 0 represents no pain while 10 represents worst possible pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Colorectal Disorders</condition>
  <arm_group>
    <arm_group_label>CONTROL: IV Lido</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CONTROL: Intravenous lidocaine, pre- and post-surgery (IV Lido)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXPERIMENTAL: Exparel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>2. Liposomal bupivacaine TAP block (experimental arm)&#xD;
Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.&#xD;
A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.&#xD;
The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.&#xD;
Adhesive tapes will be applied at the level of the TAP block puncture sites.</description>
    <arm_group_label>EXPERIMENTAL: Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Lidocaine</intervention_name>
    <description>1. Intravenous Lidocaine infusion (control arm, current standard of care)&#xD;
100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.&#xD;
1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.&#xD;
Adhesive tapes will be applied at the presumed level of TAP block puncture sites.</description>
    <arm_group_label>CONTROL: IV Lido</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-75 years&#xD;
&#xD;
          -  Elective laparoscopic colorectal surgery&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to Na Channel Blocker&#xD;
&#xD;
          -  Chronic Opioid use&#xD;
&#xD;
          -  Liver dysfunction&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Psychomotor retardation&#xD;
&#xD;
          -  BMI &gt;40&#xD;
&#xD;
          -  Sleep Apnea&#xD;
&#xD;
          -  Cardiac Rhythm Disorders&#xD;
&#xD;
          -  Planned open or concomitant procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Kasten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atrium Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atrium Health - Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <results_first_submitted>July 20, 2021</results_first_submitted>
  <results_first_submitted_qc>October 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2021</results_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Kevin Kasten</investigator_full_name>
    <investigator_title>Associate Professor and Physician, Colon and Rectal Surgery</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT04005859/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CONTROL: IV Lido</title>
          <description>CONTROL: Intravenous lidocaine, pre- and post-surgery (IV Lido)&#xD;
IV Lidocaine: 1. Intravenous Lidocaine infusion (control arm, current standard of care) n= 35&#xD;
100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.&#xD;
1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.&#xD;
Adhesive tapes will be applied at the presumed level of TAP block puncture sites.</description>
        </group>
        <group group_id="P2">
          <title>EXPERIMENTAL: Exparel</title>
          <description>EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)&#xD;
Exparel: 2. Liposomal bupivacaine TAP block (experimental arm) n= 35&#xD;
Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.&#xD;
A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.&#xD;
The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.&#xD;
Adhesive tapes will be applied at the level of the TAP block puncture sites.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CONTROL: IV Lido</title>
          <description>CONTROL: Intravenous lidocaine, pre- and post-surgery (IV Lido)&#xD;
IV Lidocaine: 1. Intravenous Lidocaine infusion (control arm, current standard of care) n= 35&#xD;
100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.&#xD;
1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.&#xD;
Adhesive tapes will be applied at the presumed level of TAP block puncture sites.</description>
        </group>
        <group group_id="B2">
          <title>EXPERIMENTAL: Exparel</title>
          <description>EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)&#xD;
Exparel: 2. Liposomal bupivacaine TAP block (experimental arm) n= 35&#xD;
Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.&#xD;
A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.&#xD;
The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.&#xD;
Adhesive tapes will be applied at the level of the TAP block puncture sites.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="16.2"/>
                    <measurement group_id="B2" value="55.8" spread="14"/>
                    <measurement group_id="B3" value="55.4" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="5.3"/>
                    <measurement group_id="B2" value="29.6" spread="8.2"/>
                    <measurement group_id="B3" value="28.4" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>On Steroids</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>H/O Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Tobacco Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior intra-abdominal surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Procedure was robotic-assisted</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="25"/>
                    <count group_id="B3" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Verbal Pain Scale (VRS) - 4 Week Post-op</title>
        <description>Postoperative pain was measured by verbal rate scale (VRS) Scale of 0-10 at instance of 4-week post-op visit (or phone call). 0 represents no pain while 10 represents worst possible pain.</description>
        <time_frame>Single VRS assessed at 4-week post-op visit (or phone call)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CONTROL: IV Lido</title>
            <description>CONTROL: Intravenous lidocaine, pre- and post-surgery (IV Lido)&#xD;
IV Lidocaine: 1. Intravenous Lidocaine infusion (control arm, current standard of care) n= 35&#xD;
100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.&#xD;
1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.&#xD;
Adhesive tapes will be applied at the presumed level of TAP block puncture sites.</description>
          </group>
          <group group_id="O2">
            <title>EXPERIMENTAL: Exparel</title>
            <description>EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)&#xD;
Exparel: 2. Liposomal bupivacaine TAP block (experimental arm) n= 35&#xD;
Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.&#xD;
A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.&#xD;
The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.&#xD;
Adhesive tapes will be applied at the level of the TAP block puncture sites.</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Pain Scale (VRS) - 4 Week Post-op</title>
          <description>Postoperative pain was measured by verbal rate scale (VRS) Scale of 0-10 at instance of 4-week post-op visit (or phone call). 0 represents no pain while 10 represents worst possible pain.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.7"/>
                    <measurement group_id="O2" value="1.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks from date of surgery (scheduled time of post-op clinic visit addressing primary endpoint of total OME utilized by patient)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CONTROL: IV Lido</title>
          <description>CONTROL: Intravenous lidocaine, pre- and post-surgery (IV Lido)&#xD;
IV Lidocaine: 1. Intravenous Lidocaine infusion (control arm, current standard of care) n= 35&#xD;
100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.&#xD;
1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.&#xD;
Adhesive tapes will be applied at the presumed level of TAP block puncture sites.</description>
        </group>
        <group group_id="E2">
          <title>EXPERIMENTAL: Exparel</title>
          <description>EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)&#xD;
Exparel: 2. Liposomal bupivacaine TAP block (experimental arm) n= 35&#xD;
Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.&#xD;
A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.&#xD;
The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.&#xD;
Adhesive tapes will be applied at the level of the TAP block puncture sites.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Opioid consumption was quite varied amongst patients, possibly contributing to underpowered study.&#xD;
Inconsistent recording of VAS while inpatient&#xD;
Inconsistent recording of VAS while undergoing 2 and 4 week post-op follow-up (clinic vs phone)&#xD;
Difficult to completely account for OME based on potential for outside prescriptions not seen by researchers.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kevin Kasten</name_or_title>
      <organization>Atrium Health</organization>
      <phone>704-355-1813</phone>
      <email>kevin.kasten@atriumhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

